

Emmanuel Egom

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1025409/publications.pdf>

Version: 2024-02-01

60
papers

1,098
citations

430754

18
h-index

434063

31
g-index

62
all docs

62
docs citations

62
times ranked

1727
citing authors

#	ARTICLE	IF	CITATIONS
1	Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyocytes against ischemic cell injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 301, H1487-H1495.	1.5	94
2	FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. <i>Journal of Molecular and Cellular Cardiology</i> , 2010, 48, 406-414.	0.9	87
3	The potential actions of angiotensin-converting enzyme II (ACE2) activator diminazene aceturate (DIZE) in various diseases. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 751-758.	0.9	74
4	Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. <i>Frontiers in Physiology</i> , 2013, 4, 130.	1.3	56
5	Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C. <i>Journal of Physiology</i> , 2015, 593, 1127-1146.	1.3	54
6	Distinct patterns of atrial electrical and structural remodeling in angiotensin II mediated atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 124, 12-25.	0.9	51
7	NPR-C (Natriuretic Peptide Receptor-C) Modulates the Progression of Angiotensin II-Mediated Atrial Fibrillation and Atrial Remodeling in Mice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006863.	2.1	46
8	Markers of Atherosclerosis: Part 1 – Serological Markers. <i>Heart Lung and Circulation</i> , 2019, 28, 667-677.	0.2	46
9	Biochemistry of Statins. <i>Advances in Clinical Chemistry</i> , 2016, 73, 127-168.	1.8	38
10	Markers of Atherosclerosis: Part 2 – Genetic and Imaging Markers. <i>Heart Lung and Circulation</i> , 2019, 28, 678-689.	0.2	36
11	Loss of insulin signaling may contribute to atrial fibrillation and atrial electrical remodeling in type 1 diabetes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 7990-8000.	3.3	33
12	Altered parasympathetic nervous system regulation of the sinoatrial node in Akita diabetic mice. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 82, 125-135.	0.9	31
13	Ezetimibe plus a Statin after Acute Coronary Syndromes. <i>New England Journal of Medicine</i> , 2015, 373, 1473-1477.	13.9	28
14	Natriuretic Peptide Receptor-C Protects Against Angiotensin II-Mediated Sinoatrial Node Disease in Mice. <i>JACC Basic To Translational Science</i> , 2018, 3, 824-843.	1.9	27
15	HDL quality or cholesterol cargo. <i>Current Opinion in Lipidology</i> , 2013, 24, 351-356.	1.2	25
16	The potential role of sphingolipid-mediated cell signaling in the interaction between hyperglycemia, acute myocardial infarction and heart failure. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 791-800.	1.5	24
17	Is the prescription right? A review of non-vitamin K antagonist anticoagulant (NOAC) prescriptions in patients with non-valvular atrial fibrillation. Safe prescribing in atrial fibrillation and evaluation of non-vitamin K oral anticoagulants in stroke prevention (SAFE-NOACS) group. <i>Irish Journal of Medical Science</i> , 2019, 188, 101-108.	0.8	23
18	TRP channels in gastric cancer: New hopes and clinical perspectives. <i>Cell Calcium</i> , 2019, 82, 102053.	1.1	23

#	ARTICLE	IF	CITATIONS
19	mTOR signalling: jack-of-all-trades. <i>Biochemistry and Cell Biology</i> , 2019, 97, 58-67.	0.9	19
20	Glycemic Variability and Vascular Complications in Patients with Type 2 Diabetes Mellitus. <i>Folia Medica</i> , 2017, 59, 270-278.	0.2	18
21	Cardioprotection in ischemia/reperfusion injury: Spotlight on sphingosine-1-phosphate and bradykinin signalling. <i>Progress in Biophysics and Molecular Biology</i> , 2010, 103, 142-147.	1.4	17
22	BNP and Heart Failure: Preclinical and Clinical Trial Data. <i>Journal of Cardiovascular Translational Research</i> , 2015, 8, 149-157.	1.1	16
23	Activation of sphingosine-1-phosphate signalling as a potential underlying mechanism of the pleiotropic effects of statin therapy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2013, 50, 79-89.	2.7	15
24	The effect of the sphingosine-1-phosphate analogue FTY 720 on atrioventricular nodal tissue. <i>Journal of Cellular and Molecular Medicine</i> , 2015, 19, 1729-1734.	1.6	15
25	Mechanisms of renal hyporesponsiveness to BNP in heart failure. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015, 93, 399-403.	0.7	15
26	An update on the 2014 Ebola outbreak in Western Africa. <i>Asian Pacific Journal of Tropical Medicine</i> , 2017, 10, 6-10.	0.4	15
27	Novel bradykinin signaling in adult rat cardiac myocytes through activation of p21-activated kinase. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2010, 298, H1283-H1289.	1.5	14
28	A natriuretic peptides clearance receptor's agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure. <i>Biomedicine and Pharmacotherapy</i> , 2017, 93, 1144-1150.	2.5	12
29	Pulmonary Arterial Hypertension Due to NPR-C Mutation: A Novel Paradigm for Normal and Pathologic Remodeling?. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3063.	1.8	12
30	Updates on sphingolipids: Spotlight on retinopathy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 143, 112197.	2.5	11
31	New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2017, 9, 112-118.	0.8	10
32	Simvastatin in Moderate-to-Severe COPD. <i>New England Journal of Medicine</i> , 2014, 371, 969-971.	13.9	9
33	Effect of sphingosine-1-phosphate on L-type calcium current and Ca ²⁺ transient in rat ventricular myocytes. <i>Molecular and Cellular Biochemistry</i> , 2016, 419, 83-92.	1.4	9
34	Determination of Sphingosine-1-Phosphate in Human Plasma Using Liquid Chromatography Coupled with Q-ToF Mass Spectrometry. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1800.	1.8	9
35	Evolving use of natriuretic peptide receptor type-C as part of strategies for the treatment of pulmonary hypertension due to left ventricle heart failure. <i>International Journal of Cardiology</i> , 2019, 281, 172-178.	0.8	9
36	Global Longitudinal Strain and Strain Rate in Type Two Diabetes Patients with Chronic Heart Failure: Relevance to Osteoprotegerin. <i>Folia Medica</i> , 2016, 58, 164-173.	0.2	6

#	ARTICLE	IF	CITATIONS
37	A novel method for left anterior coronary artery flow velocity assessment by transthoracic echocardiography at the peak of a supine bicycle test. <i>Acta Radiologica</i> , 2016, 57, 1056-1065.	0.5	6
38	A comparison of characteristics and outcomes of patients with community-acquired and hospital-acquired COVID-19 in the United Kingdom: An observational study. <i>Respiratory Medicine</i> , 2021, 178, 106314.	1.3	6
39	Sphingosine-1-phosphate signalling as a therapeutic target for patients with abnormal glucose metabolism and ischaemic heart disease. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 517-524.	0.6	5
40	Latest Updates on Lipid Management. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2019, 26, 85-100.	1.0	5
41	Natriuretic Peptide Clearance Receptor (NPR-C) Pathway as a Novel Therapeutic Target in Obesity-Related Heart Failure With Preserved Ejection Fraction (HFpEF). <i>Frontiers in Physiology</i> , 2021, 12, 674254.	1.3	5
42	Letter From Egom Regarding Article, "High-Density Lipoprotein Cholesterol, Size, Particle Number, and Residual Vascular Risk After Potent Statin Therapy". <i>Circulation</i> , 2014, 129, e480.	1.6	4
43	HDL-C/HDL-P Ratio. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2576.	1.2	4
44	LDL-Cholesterol and Atherosclerotic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 705-706.	1.2	4
45	The therapeutic effect of B-type natriuretic peptides in acute decompensated heart failure. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2020, 47, 1120-1133.	0.9	4
46	A therapeutic approach to hyperglycaemia in the setting of acute myocardial infarction: spotlight on glucagon-like peptide 1. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2012, 6, 213-219.	1.0	3
47	Is there a way out for the 2014 Ebola outbreak in Western Africa?. <i>Asian Pacific Journal of Tropical Medicine</i> , 2015, 8, 773-778.	0.4	3
48	Time to redefine body mass index categories in chronic diseases? Spotlight on obesity paradox. <i>International Journal of Food Sciences and Nutrition</i> , 2018, 69, 513-523.	1.3	3
49	Dynamic changes of the composition of plasma HDL particles in patients with cardiac disease: Spotlight on sphingosine-1-phosphate/serum amyloid A ratio. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 319-325.	0.9	3
50	Identifying Potential Mutations Responsible for Cases of Pulmonary Arterial Hypertension. <i>The Application of Clinical Genetics</i> , 2021, Volume 14, 113-124.	1.4	3
51	Life-threatening hyponatraemia. <i>BMJ Case Reports</i> , 2011, 2011, bcr1220103594-bcr1220103594.	0.2	2
52	B-type natriuretic peptide and heart failure: what can we learn from clinical trials?. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2015, 42, 881-887.	0.9	1
53	Pregnancy and breastfeeding during COVID-19 pandemic. <i>Therapeutic Advances in Reproductive Health</i> , 2020, 14, 263349412096252.	1.3	1
54	The Sphingosine-1-phosphate Receptor Agonist FTY720 Increases Heart Rate Variability In Isolated Murine Ischemic Heart Model. <i>Cardiovascular Pharmacology: Open Access</i> , 2013, 02, .	0.1	0

#	ARTICLE	IF	CITATIONS
55	PS 04-18 THE EFFECT OF THE SPHINGOSINE-1-PHOSPHATE ANALOGUE FTY720 ON ATRIOVENTRICULAR NODAL TISSUE. <i>Journal of Hypertension</i> , 2016, 34, e138.	0.3	0
56	Atrial Fibrillation in Hypertensive Heart Disease is Associated with Distinct Patterns of Electrical Remodeling in the Left and Right Atria. <i>Biophysical Journal</i> , 2017, 112, 235a.	0.2	0
57	Plasma Sphingolipidome as a Surrogate for Human Metabolic Health. <i>Journal of the American College of Cardiology</i> , 2018, 71, 814-815.	1.2	0
58	The role of Natriuretic Peptide Receptor C in atrial electrophysiological remodelling in hypertensive heart disease. <i>Journal of Molecular and Cellular Cardiology</i> , 2018, 124, 89.	0.9	0
59	Role of natriuretic peptide receptor C signalling in obesity-induced heart failure with preserved ejection fraction with pulmonary hypertension. <i>Pulmonary Circulation</i> , 2020, 10, 1-2.	0.8	0
60	8. Sphingosine-1-phosphate-rich high-density lipoprotein in cardiovascular health and disease. <i>Human Health Handbooks</i> , 2016, , 137-154.	0.1	0